Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study - Liming Wang1,2,3,
- Jeffrey Wiener8,
- Marc Bulterys1,9,a,
- Xiaoyu Wei1,
- Lili Chen6,
- Wei Liu7,
- Shujia Liang7,
- Colin Shepard1,9,
- Linhong Wang4,
- Ailing Wang4,
- Fujie Zhang2,3,5,b and
- Athena P. Kourtis8,b
- 1Global AIDS Program China Office, Division of HIV and Tuberculosis, Center for Global Health, US Centers for Disease Control and Prevention (CDC)
- 2Beijing Ditan Hospital
- 3Clinical Center for HIV/AIDS, Capital Medical University
- 4National Center for Women and Children's Health
- 5National Center for AIDS/STD Prevention and Control, Chinese Center for Disease Control and Prevention, Beijing
- 6Guangxi Zhuang Autonomous Region Health and Family Planning Commission
- 7Guangxi Provincial Center for Disease Control and Prevention, Nanning, China
- 8Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion
- 9Center for Global Health, CDC, Atlanta, Georgia
- Correspondence: A. P. Kourtis, Division of Reproductive Health, NCCDPHP, CDC, F74, 4770 Buford Hwy NE, Atlanta, GA 30341 (apk3{at}cdc.gov).
-
↵a Present affiliation: Global Hepatitis Programme, World Health Organization (WHO), Geneva, Switzerland. -
↵b F. Z. and A. P. K. contributed equally to this work.
Abstract Background. There is limited information on antiviral therapy for hepatitis B virus (HBV) infection among pregnant women coinfected with human immunodeficiency virus (HIV) and HBV. Methods. A phase 2 randomized, controlled trial of a regimen containing tenofovir (TDF)/lamivudine (3TC) and a regimen containing 3TC in HIV/HBV-coinfected pregnant women in China. The HBV virological response was compared in study arms. Results. The median decline in the HBV DNA level was 2.60 log10 copies/mL in the TDF/3TC arm and 2.24 log10 copies/mL in the 3TC arm (P = .41). All women achieved HBV DNA levels of <6 log10 copies/mL at delivery. Conclusions. Initiation of either regimen led to achievement of HBV DNA levels below the threshold associated with perinatal HBV transmission. Clinical Trials Registration. NCT01125696.
Key words |